Cited 9 times in
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.date.accessioned | 2019-07-23T07:02:11Z | - |
dc.date.available | 2019-07-23T07:02:11Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/170431 | - |
dc.description.abstract | PURPOSE: The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). MATERIALS AND METHODS: We conducted a multi-center randomized phase II trial to compare the clinical outcomes between pemetrexed plus cisplatin combination therapy followed by maintenance pemetrexed (PC) and pemetrexed monotherapy (P) after failure of first-line EGFR-TKI. The primary objective was progression-free survival (PFS), and secondary objectives included overall response rate (ORR), overall survival (OS), health-related quality of life (HRQOL), and safety and toxicity profiles. RESULTS: A total of 96 patientswere randomized, and 91 patientswere treated at 14 centers in Korea. The ORR was 34.8% (16/46) for the PC arm and 17.8% (8/45) for the P arm (p=0.066). With 23.4 months of follow-up, the median PFS was 5.4 months in the PC arm and 6.4 months in the P arm (p=0.114). The median OS was 17.9 months and 15.7 months in PC and P arms, respectively (p=0.787). Adverse events ≥ grade 3 were reported in 12 patients (26.1%) in the PC arm and nine patients (20.0%) in the P arm (p=0.491). The overall time trends of HRQOL were not significantly different between the two arms. CONCLUSION: The outcomes of pemetrexed therapy in NSCLC patients with disease progression after firstline EGFR-TKI might not be improved by adding cisplatin. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Kwai Han Yoo | - |
dc.contributor.googleauthor | Su Jin Lee | - |
dc.contributor.googleauthor | Jinhyun Cho | - |
dc.contributor.googleauthor | Ki Hyeong Lee | - |
dc.contributor.googleauthor | Keon Uk Park | - |
dc.contributor.googleauthor | Ki Hwan Kim | - |
dc.contributor.googleauthor | Eun Kyung Cho | - |
dc.contributor.googleauthor | Yoon Hee Choi | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Hoon-Gu Kim | - |
dc.contributor.googleauthor | Heui June Ahn | - |
dc.contributor.googleauthor | Ha Yeon Lee | - |
dc.contributor.googleauthor | Hwan Jung Yun | - |
dc.contributor.googleauthor | Jin-Hyoung Kang | - |
dc.contributor.googleauthor | Jaeheon Jeong | - |
dc.contributor.googleauthor | Moon Young Choi | - |
dc.contributor.googleauthor | Sin-Ho Jung | - |
dc.contributor.googleauthor | Jong-Mu Sun | - |
dc.contributor.googleauthor | Se-Hoon Lee | - |
dc.contributor.googleauthor | Jin Seok Ahn | - |
dc.contributor.googleauthor | Keunchil Park | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.identifier.doi | 10.4143/crt.2018.324 | - |
dc.contributor.localId | A01166 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 30177585 | - |
dc.subject.keyword | Cisplatin | - |
dc.subject.keyword | Epidermalgrowthfactorreceptor | - |
dc.subject.keyword | Mutation | - |
dc.subject.keyword | Non-smallcelllungcarcinoma | - |
dc.subject.keyword | Pemetrexed | - |
dc.subject.keyword | Quality of life | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.citation.volume | 51 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 718 | - |
dc.citation.endPage | 726 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.51(2) : 718-726, 2019 | - |
dc.identifier.rimsid | 62333 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.